With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1122-10-7,3,4-Dibromo-1H-pyrrole-2,5-dione,as a common compound, the synthetic route is as follows.
To a solution of 3,4-dibromomaleimide (1.00g, 3.9mmol) and N-methylmorpholine (0.43ml_, 3.90mmol) in THF (50ml_), methylchloroformate (0.30ml_, 3.90mmol) was added and the mixture was stirred for 20minutes at room temperature. To this mixture, dichloromethane (DCM, 40ml_) was added and the organic phase was washed with water (3x100ml_), dried with MgS04. The solvent was removed in vacuo to yield the titled product as a purple powder. 1H NMR (CDCIs, 300MHz) d (ppm): 4.01 (3H, s, COCH3). 13C NMR(CDCI3, 75MHz) d (ppm): 131 .4(C=C), 54.8 (COCH3).
The synthetic route of 1122-10-7 has been constantly updated, and we look forward to future research findings.
Reference£º
Patent; UNILEVER PLC; UNILEVER N.V.; CONOPCO, INC., D/B/A UNILEVER; KHOSHDEL, Ezat; BATES, Susan; HAND, Rachel, Alice; HADDLETON, David, Mark; KIRBY, Gavin, William; (20 pag.)WO2019/201787; (2019); A1;,
Pyrroline – Wikipedia
1-Pyrroline | C4H7N – PubChem